Doctor Accused of Diluting Chemo, Bilking Medicare Pleads Guilty

The founder of the Rose Cancer Center, oncologist Dr. Meera Sachdeva, along with her billing agent Monica Weeks, pled guilty in U.S. District Court for their roles in a multimillion-dollar health care fraud case that put many patients at serious risk while allowing Sachdeva to bilk health insurers and patients for their own profits.

The Rose Cancer Center was located in the south Mississippi town of Summit in 2005. Prosecutors claim that Sachdeva re-used old needles, diluted chemotherapy drugs administered at the cancer center and massively overbilled insurance companies in the pursuit of profits. Her fraudulent charges to Medicare and Medicaid total over $15 million alone, not including billing to private insurers.

Ultimately the defendants have pled guilty to one count of health care fraud and two counts of making false statements. They are now staring at a possible 20-year prison sentence—significantly lower than the 165 possible years they had faced had they been convicted on all of the original counts. By pleading guilty, Sachdeva and her co-defendant reached a deal to have some of the other charges against them dropped.

In court, Sachdeva's lawyer did the talking, denying the charge of diluting chemotherapeutic drugs administered at the cancer center, which is far and away the most serious and most dispicable charge.

One patient reported to the Associated Press that he developed a pair of bacterial infections following treatment at the Rose Cancer Center and faces possible infection from several serious viruses. Later it was determined by the Mississippi Health Department that 11 patients developed similar bacterial infections, which led the department to shut down Sachdeva's clinic in July of 2011.

Sachdeva and Weeks are to be sentenced in October.

Source: Huffington Post

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap